Griffin: Accessing functional antibodies from serum without B cells
Griffin is a platform for sequencing polyclonal antibodies using mass spectrometry. Since 2009, Abterra Biosciencs founders and employees have been developing novel methods for sequencing antibody proteins directly. Our monoclonal antibody sequencing service, Valens, has been used to successfully sequence hundreds of antibodies without the need for B cells. Now, with Griffin, we can sequencing complex mixes of antibodies directly from patient serum, or from immunized animals.
Watch our CEO, Dr. Natalie Castellana’s presentation on Unlocking the Serum Antibody Repertoire: Accessing Functional Antibodies without B Cells to learn how Griffin works.
Click below to watch the presentation.
Related Posts
Abterra Bio Seattle Angel Conference Winner
We’re excited to announce that Abterra Bio has been chosen as the Winner of the 19th Seattle Angel Conference and the Audience Favorite Award. This year, there were 81 start-up companies from all over the US that had applied. The selection process took around 2-3...
Digital Proteomics is Abterra Biosciences
We're excited to announce that Digital Proteomics is now Abterra Biosciences. Our vision for the business has evolved and it's time to realign our name with our capabilities; we have developed core technologies that are driving our partners' antibody discovery...
We are a CONNECT Cool Company 2021!
We’re excited to announce that Abterra Biosciences has been selected as "A Cool Company" for the second year in a row by CONNECT. CONNECT, a premier innovation company accelerator in San Diego that creates and scales great companies in the technology and life sciences...
Get In Touch